Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P61254

UPID:
RL26_HUMAN

ALTERNATIVE NAMES:
60S ribosomal protein L26

ALTERNATIVE UPACC:
P61254; B2R4F0; D3DTR8; Q02877; Q6IPY2

BACKGROUND:
Large ribosomal subunit protein uL24, known alternatively as 60S ribosomal protein L26, is integral to the ribosome's large subunit, facilitating protein synthesis. This process is essential for cellular health and organismal development, making uL24 a key player in the cellular machinery.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Large ribosomal subunit protein uL24 could open doors to potential therapeutic strategies. Its involvement in Diamond-Blackfan anemia 11, through gene variants, underscores its significance in disease mechanisms and the development of gene-targeted therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.